Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22642273 | 0.89 | MEN1 (0.46) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL9079587 | 0.87 | MEN1 (0.56) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL73418 | 0.87 | LOXL2 (0.53) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL18239583 | 0.87 | CA12 (0.54) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL20215649 | 0.87 | MAPT (0.44) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL21635601 | 0.84 | ALDH1A1 (0.58) | ESR1LMNACYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL4668174 | 0.84 | CA12 (0.56) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL5477407 | 0.84 | CA12 (0.50) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL454324 | 0.83 | ALDH1A1 (0.53) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL1987238 | 0.83 | KMT2A (0.50) | KMT2ALMNAMAOASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236102-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3736275-A1 | OXABICYCLOHEPTANE PRODRUGS FOR USE IN TREATING CANCER | Lixte Biotechnology, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2019216810-A1 | NEW ANTIFUNGAL COMPOUNDS | URBAN CONSTANTIN (SE) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019216810-A1 | NEW ANTIFUNGAL COMPOUNDS | URBAN CONSTANTIN (SE) | 2019-11-14 | — | — | WO | disclosed |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-1944303-B1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| US-8158657-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-4918176-A | SYSTEMIC AND TOPICAL TREATMENT OF DERMATOLOGIC DISORDERS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1990-04-17 | — | — | US | disclosed |
| EP-0350846-A2 | Condensed heterocyclic compounds and their use in therapy | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-17 | — | — | EP | disclosed |
| US-4876381-A | Naphthalene derivatives possessing a retinoid-type action, processes for their preparation, and medicinal and cosmetic compositions containing these derivatives | L'OREAL (FR) | 1989-10-24 | — | — | US | disclosed |
| US-4788213-A | TREATING ACNE AND PSORIASIS | HOFFMAN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4783549-A | Benzonorbornene derivatives, processes for their preparation and medicinal and cosmetic compositions containing them | L'OREAL (FR) | 1988-11-08 | — | — | US | disclosed |
| US-4775663-A | SKIN, EYE DISORDERS; ATROPHY, CARCINOMAS FROM SUNLIGHT | L'OREAL (FR) | 1988-10-04 | — | — | US | disclosed |
| US-4766235-A | SKIN DISORDERS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1988-08-23 | — | — | US | disclosed |
| US-4678793-A | ACNE, PSORIASIS, ANTITUMOR | HOFFMANN-LA ROCHE INC. (US) | 1987-07-07 | — | — | US | disclosed |
| US-4439614-A | INHIBITING TUMOR PRODUCTION IN SKIN | SRI INTERNATIONAL (US) | 1984-03-27 | — | — | US | disclosed |
| US-4326055-A | ANTITUMOR AGENTS, SKIN DISORDERS, RHEUMATIC DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | MEN1 2175/4885KMT2A 2426/4885CA1 1325/4885 |
| US-11236102-B2 | Oxabicycloheptane prodrugs | UGT2B7, UGT1A6, UGT1A1 | MEN1 2175/4885KMT2A 2426/4885CA1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.